Table 1.
Characteristics of the study population
| Characteristic | Valid cases* | Measure | |
|---|---|---|---|
| Patients | 291 | 291 | |
| Patient related | Men (n, %) | 291 | 159, 54.6% |
| Age in years (median, Q1–Q3) | 290 | 67, 59–73 | |
| ΒΜΙ in kg/m2 (median, Q1–Q3) | 289 | 26.0, 22.8–29.4 | |
| Alcohol consumption | 265 | 39.2% | |
| Smokers (ex or current) | 274 | 67.2% | |
| Cardiovascular disease | 277 | 59.8% | |
| Diabetes | 276 | 31.9% | |
| Respiratory disease | 276 | 32.3% | |
| Dyslipidemia | 276 | 38.8% | |
| Thrombosis history VTE | 291 | 15.5% | |
| Thrombosis history ATE | 291 | 3.8% | |
| ECOG PS | 291 | ||
| 0 | 26.8% | ||
| 1 | 46.1% | ||
| 2 | 26.1% | ||
| Treatment related | HTAs | 291 | 97.9% |
| Surgery | 291 | 26.5% | |
| Central venous catheter | 222 | 22.5% | |
| Cancer related | Metastasis | 291 | 72.9% |
| Gastrointestinal system | 37.1% | ||
| Lung | 22.7% | ||
| Woman reproductive system | 16.2% | ||
| Breast | 8.9% | ||
| Urothelial system | 8.3% | ||
| Head and neck | 2.4% | ||
| Other (or unknown) | 4.5% |
BMI body mass index, HTAs highly thrombogenic agents, including erythropoietin
*Number of patents with available/valid data